Free tool
FAERS Monitor: Risperdal
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020272 or its brand name (Risperdal, Risperidone). Reports on generic versions are filed under their own applications.
Reports
121,516
Serious
83,453
69% of reports
Hospitalization
38,138
Death reported
9,507
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- gynaecomastia24,464
- off label use12,012
- abnormal weight gain9,410
- weight increased8,935
- drug ineffective7,389
- product use in unapproved indication5,942
- emotional disorder5,911
- injury4,618
- drug interaction4,510
- hyperprolactinaemia4,424
- somnolence4,365
- galactorrhoea3,705
- obesity3,695
- emotional distress3,516
- extrapyramidal disorder3,381
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,082 |
| 2005 | 2,052 |
| 2006 | 2,349 |
| 2007 | 2,212 |
| 2008 | 2,285 |
| 2009 | 3,901 |
| 2010 | 3,696 |
| 2011 | 3,714 |
| 2012 | 3,761 |
| 2013 | 3,058 |
| 2014 | 4,161 |
| 2015 | 12,643 |
| 2016 | 13,493 |
| 2017 | 13,038 |
| 2018 | 6,712 |
| 2019 | 7,593 |
| 2020 | 6,046 |
| 2021 | 4,893 |
| 2022 | 5,329 |
| 2023 | 4,918 |
| 2024 | 5,290 |
| 2025 | 4,848 |
| 2026 | 3,441 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,932,643 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gynaecomastiaSignal | 24,464 | 647.9 | 630.8 | 3,323,626 |
| abnormal weight gainSignal | 9,410 | 548.6 | 526.6 | 1,229,701 |
| hyperprolactinaemiaSignal | 4,424 | 369.1 | 350.4 | 516,798 |
| galactorrhoeaSignal | 3,705 | 234.2 | 223.0 | 364,631 |
| obesitySignal | 3,695 | 52.0 | 50.1 | 141,946 |
| emotional disorderSignal | 5,911 | 40.8 | 39.7 | 185,875 |
| extrapyramidal disorderSignal | 3,381 | 27.1 | 26.2 | 73,546 |
| injurySignal | 4,618 | 12.1 | 11.7 | 44,065 |
| weight increasedSignal | 8,935 | 7.2 | 7.0 | 45,873 |
| emotional distressSignal | 3,516 | 5.1 | 5.0 | 11,470 |
| drug interactionSignal | 4,510 | 5.0 | 4.9 | 14,274 |
| product use in unapproved indicationSignal | 5,942 | 4.2 | 4.1 | 14,456 |
| somnolenceSignal | 4,365 | 3.8 | 3.7 | 8,946 |
| off label useSignal | 12,012 | 2.4 | 2.4 | 10,028 |
| drug ineffective | 7,389 | 1.0 | 0.9 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.